The ever-emerging developments and innovations on the advanced translational strategies for diagnosing and treating fatal human diseases are substantially re-shaping our future and improving the human health quality. Compared to traditional approaches (including medical imaging, biopsy, surgery, chemo- and radiotherapy, etc.), early-stage molecular diagnosis with trace bio-specimen, real-time detection by visualized medical technologies, cutting-edge surgical robots with precision manipulations, remotely-controlled telemedicine and artificial intelligence (AI)-aided lesion determination have affected revolutionary influences to current medical modalities and future perspectives.

The ongoing COVID-19 pandemic in early 2020 taught us another lesson on our understanding of the importance and necessity to upgrade our capability to prevent and cope with infectious diseases. Accessible test, fast diagnosis, prompt vaccine development and efficacious patient treatment along with restrict disease control will definitely lead to a successful fight against COVID-19 outbreak and recovery back to normal status of the whole society. During this process, we have witnessed actual and vast translations and clinical applications of versatile advanced strategies, which further encourages us to propose this special issue.

Several mini-review manuscripts have been published in this collection among which fundamental principles, techniques, devices and applications have been broadly discussed. Researchers focused on the noninvasive treatments of diseases in central nervous systems (CNS). Bozinov reported recent advances of laser interstitial thermal therapy in gliomas. De Almeida Bastos et al. further put the emphasis on the laser interstitial thermal therapy in the treatment of brain metastases and radiation necrosis. Hu et al. summarized the imaging of intratumoral heterogeneity in high-grade gliomas, and Zhang et al. featured the latest advancements of glioblastoma precision therapy as well as its bright outlook from bench to clinic translations. Besides that, Chen told a full story on the organoid models in lung regeneration and cancers. Balier analyzed the advances in image enhancement for sarcoma surgery. Hu shared their experiences on the percutaneous vertebral augmentation procedures in the management of spinal metastases.

As for the advanced analytical techniques, Dr. Weller wrote a review on the topic of liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. Dr. Baker summarized state-of-the-art developments of biofluid diagnosis by FTIR spectroscopy as a platform technology for cancer detections.

In the past decades, a variety of functional biomaterials from macro-, micro-to nano-dimensional scales have been playing an active role in the diagnostic modality and disease-oriented treatments. To highlight their roaring importance in medicine, Chen et al. worked out with a summary on the choice of anti-tumor strategies based on micro-molecules or drug loading function of biomaterials. As a specific utility in ultrasound imaging, Dr. Liu sum up their own research and provide a comprehensive discussion on the ultrasound-mediated diagnostic imaging and advanced treatments with multifunctional micro/nanobubbles. Dr. Beccaria focused on the ultrasound-induced blood-brain barrier (BBB) disruptions and the clinical treatments for gliomas and other primary CNS tumors.

In conclusion, several investigators including basic research scientists and medical doctors submitted their articles describing recent breakthroughs in the fields of cancer therapy, biomedical engineering, material sciences and their translational medicine. These researchers within a transdisciplinary community shared this collection on the hot topics of noninvasive treatment strategies, theranostic solutions on fatal diseases including cancers and brain diseases, new-generation analytical devices for enhanced diagnosis and precision treatment and from-bench-to-bed medical translations into clinical uses. It is believed that these valuable contributions will also shed inspirations to the industrial for their innovative medical equipment that serves our healthcare and disease treatments better in the coming decades especially in the era of embracing advanced translational evolutions.
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